@article{3201346,
    title = "Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas.",
    author = "Stamouli, Maria and Gkirkas, Konstantinos and Karagiannidi, Aggeliki and Iliakis, Theodoros and Chondropoulos, Spiros and Thomopoulos, Thomas and Nikolaou, Vassiliki and Pappa, Vassiliki and Papadavid, Evangelia and Tsirigotis, Panagiotis",
    journal = "Clinical hematology international",
    year = "2021",
    volume = "3",
    number = "2",
    pages = "72--76",
    doi = "10.2991/chi.k.210529.001",
    keywords = "allogeneic stem cell transplantation, cutaneous t-cell lymphomas, donor lymphocyte infusion, graft versus lymphoma, graft-versus-host disease, Mycosis fungoides, sezary syndrome",
    abstract = "The prognosis of patients with mycosis fungoides (MF) and Sezary Syndrome (SS) varies greatly, from near normal life expectancy in patients with early stage, to a  median survival of less than 2 years for those diagnosed with advanced stage  disease. Initial response to treatment is almost always followed by relapse and,  finally, most of patients enter a phase of advanced multi-drug resistant disease  with a short life expectancy after multiple lines of treatment. Allogeneic stem cell  transplantation (allo-SCT) is usually limited to patients with advanced disease  resistant to multiple treatments. Retrospective registry-based studies have shown  increased Non-relapse Mortality (NRM) rates in patients with poor performance  status, as well as in patients treated with myeloablative conditioning regimens.  Another major limitation of allo-SCT is the increased relapse rate which occurs in  nearly 50% of the cases, and is probably due to the fact that only heavily  pretreated patients with advanced disease are referred for allo-SCT. Due to the  paucity of data, the ideal conditioning regimen which will provide the maximum  therapeutic benefit without the cost of increased NRM is not currently known. In  this article we present our experience with a novel regimen in the treatment of  patients with advanced MF/SS."
}